Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment

Mise à jour : Il y a 4 ans
Référence : NCT02696642

Femme et Homme

Extrait

To characterize the safety, tolerability, pharmacokinetics and immunogenicity of anetumab ravtansine in subjects with advanced solid cancers and with different degrees of hepatic or renal impairment


Critère d'inclusion

  • Neoplasms

Liens